Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Gene Mutation Negative”

66 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 66 results

Testing effectiveness (Phase 2)Ended earlyNCT01351038
What this trial is testing

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Who this might be right for
KRAS Wild TypeResectable Type II Gastric Adenocarcinoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 43
Testing effectiveness (Phase 2)Ended earlyNCT01522612
What this trial is testing

Colorectal Cancer (CRC) Cetuximab Elderly Frail

Who this might be right for
Colorectal Cancer Metastatic
European Organisation for Research and Treatment of Cancer - EORTC 5
Not applicableEnded earlyNCT01074333
What this trial is testing

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Who this might be right for
Colorectal Neoplasm
Merck KGaA, Darmstadt, Germany 146
Not applicableStudy completedNCT01082315
What this trial is testing

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Who this might be right for
Colorectal Neoplasms
Merck KGaA, Darmstadt, Germany 730
Testing effectiveness (Phase 2)Ended earlyNCT01504477
What this trial is testing

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Georgetown University 6
Testing effectiveness (Phase 2)Temporarily pausedNCT01088620
What this trial is testing

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
WiSP Wissenschaftlicher Service Pharma GmbH 134
Testing effectiveness (Phase 2)Study completedNCT01229150
What this trial is testing

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Who this might be right for
Non Small Cell Lung Carcinoma
National Cancer Institute (NCI) 89
Early research (Phase 1)Study completedNCT01294826
What this trial is testing

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Who this might be right for
Recurrent Colon CancerRecurrent Rectal CancerStage IV Colon Cancer+3 more
Swedish Medical Center 20
Testing effectiveness (Phase 2)Study completedNCT02399943
What this trial is testing

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Who this might be right for
Colorectal CancerKRAS WildtypeNRAS Wildtype+1 more
University Health Network, Toronto 14
Testing effectiveness (Phase 2)Ended earlyNCT01523639
What this trial is testing

A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis

Who this might be right for
Colorectal CancerSteatohepatitis
Austrian Breast & Colorectal Cancer Study Group 8
Early research (Phase 1)Study completedNCT01451632
What this trial is testing

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Who this might be right for
Colorectal CancerSquamous Cell Head and Neck CancerNon-small Cell Lung Cancer+2 more
Merrimack Pharmaceuticals 48
Testing effectiveness (Phase 2)Ended earlyNCT01060423
What this trial is testing

TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer
Hans-Joachim Schmoll, MD 8
Testing effectiveness (Phase 2)Looking for participantsNCT07064018
What this trial is testing

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Who this might be right for
Soft-tissue SarcomaTriple Negative Breast CancerNon-small Cell Lung Cancer+3 more
University of California, Irvine 67
Testing effectiveness (Phase 2)Study completedNCT01836653
What this trial is testing

Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Who this might be right for
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
EPS Corporation 122
Testing effectiveness (Phase 2)Study completedNCT00803647
What this trial is testing

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Who this might be right for
Metastatic Colorectal Cancer
NSABP Foundation Inc 20
Early research (Phase 1)Looking for participantsNCT06585488
What this trial is testing

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Who this might be right for
Metastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung CancerAdvanced Colorectal Cancer+4 more
BeiGene 514
Testing effectiveness (Phase 2)UnknownNCT01388621
What this trial is testing

Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
WiSP Wissenschaftlicher Service Pharma GmbH 140
Testing effectiveness (Phase 2)Study completedNCT01443377
What this trial is testing

Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer

Who this might be right for
Rectal Cancer
National Center for Tumor Diseases, Heidelberg 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT04117945
What this trial is testing

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal Adenocarcinoma+10 more
Academic and Community Cancer Research United 22
Testing effectiveness (Phase 2)Ended earlyNCT01925274
What this trial is testing

PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Pfizer 19
Load More Results